Study of Ibrutinib in Subjects With Acute Myeloid Leukemia
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
9 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- City of Hope
Duarte, California, United States
- Uc Davis Medical Center
Sacramento, California, United States
- the University of Chicago Medical Center
Chicago, Illinois, United States
- University of Iowa
Iowa City, Iowa, United States
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland, United States
- Roswell Park Cancer Institute
Buffalo, New York, United States
- Montefiore Einstein Center for Cancer Research
The Bronx, New York, United States
- Md Anderson Cancer Center
Houston, Texas, United States
- Fred Hutchinson Cancer Research Center
Seattle, Washington, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 28 Feb 2015
- Primary completion
- 30 Apr 2017
- Completion
- 30 Apr 2017
- Last update posted
- 14 Aug 2018
- Registered enrollment
- 36
- Registry id
- NCT02351037
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.